Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Not recruiting

Study on the Effectiveness and Safety of AP707 and Naproxen for Patients with Chronic Back Pain

Verified siteRegistered drug
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

What is this trial about?

A plain-language summary of the goals, design and what participants do

This clinical trial is focused on evaluating the effectiveness and safety of a treatment called AP707 for individuals experiencing chronic back pain. Chronic back pain is a long-lasting pain in the back that persists for at least three months. The study aims to determine how well AP707 works as an additional treatment for managing this type of pain.

Participants in the study will be divided into two groups. One group will receive the AP707 treatment, while the other group will receive a placebo. The study will last for a total of 52 weeks, with assessments at various points to monitor changes in pain levels and overall well-being. The main goal is to see if AP707 can help reduce pain and improve the quality of life for those with chronic back pain.

Throughout the study, participants will be asked to report their pain levels and any changes they experience. The study will also look at other factors such as sleep quality, psychological distress, and overall health. By the end of the study, researchers hope to gather valuable information on the potential benefits of AP707 for managing chronic back pain.

The research process

The trial runs in 6 steps – from screening to follow-up. Each step says what happens and what the team monitors.

  1. Step 1

    Joining the study

    Upon joining the study, you will be required to sign and date an informed consent form. This document confirms your understanding and agreement to participate in the clinical trial.

    You will complete the painDETECT questionnaire, which assesses your pain level. A score of 20 or more is necessary to proceed.

  2. Step 2

    Initial assessment

    An initial assessment will be conducted to confirm that you have experienced chronic back pain for at least three months.

    Your current pain intensity will be measured using the Numeric Rating Scale (NRS), where you will rate your pain from 0 to 10. A score greater than 5 is required.

  3. Step 3

    Randomized treatment phase

    You will be randomly assigned to one of two groups: one receiving the active treatment, AP707, and the other receiving a placebo.

    The treatment will be administered as a sublingual spray, which means it is sprayed under the tongue. The appearance of the spray is brown-beige with a sweet and slightly fruity odor.

  4. Step 4

    Treatment week 14

    At the end of the first treatment phase, your pain level will be reassessed using the NRS to evaluate any changes from the baseline.

    Additional assessments will include the Neuropathic Pain Symptom Inventory (NPSI) questionnaire to measure changes in pain symptoms.

  5. Step 5

    Treatment week 26

    At the end of the second treatment phase, your pain level will again be measured using the NRS.

    Further assessments will be conducted to evaluate changes in psychological distress, quality of life, and sleep quality.

  6. Step 6

    Treatment week 52

    At the end of the third treatment phase, a final assessment of your pain level will be conducted using the NRS.

    The study will also evaluate changes in your overall impression of change, quality of life, and any adverse events experienced during the trial.

Who can join the trial?

10 criteria

  • Signed and dated informed consent form.
  • Completed painDETECT questionnaire with a score of 20 or more. This is a survey to help understand your pain.
  • Patients with chronic back pain for at least 3 months.
  • Female and male patients who are 18 years or older.
  • Patients with more than 1 year life expectancy.
  • Patients with optimized sCPT on study entry. This means your current treatment plan is stable and as good as it can be.
  • Willingness to use reliable contraception during the study and for three months after taking the last study medication.
  • Good command of the German language to understand questionnaires in German.
  • Current moderate to severe pain with pain intensity greater than 5 on a Numeric Rating Scale (NRS, 0 - 10). This means you have a significant need for more pain treatment.
  • Completed QUISS (Quantification Inventory for Somatoform Syndromes) questionnaire with a score of 45 or less. This is another survey to assess your symptoms.

Who cannot join the trial?

10 criteria

  • Patients with any other significant health condition that might interfere with the study.
  • Patients who are currently participating in another clinical trial.
  • Patients who have had a recent surgery or are planning to have surgery during the study period.
  • Patients who are pregnant or breastfeeding.
  • Patients with a history of substance abuse or addiction.
  • Patients who are unable to comply with the study procedures.
  • Patients with known allergies to the study medication or its ingredients.
  • Patients with severe mental health disorders that are not well controlled.
  • Patients who have been diagnosed with cancer in the past five years.
  • Patients with severe liver or kidney disease.
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

We usually reply within a few days

Verified sites

All sites with verified contact details – recruitment status may not be available; ask directly

Trial locations

Where you can join this trial

Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.

Not recruiting
Not finding your country?

Not sure what to do next?

Joining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.

See the full process and FAQ

Investigated drugs

AP707 is a medication being tested to see how well it works for people who have long-lasting back pain. It is used in addition to other treatments that patients might already be receiving. The goal is to find out if adding AP707 can help reduce pain and improve the quality of life for those suffering from chronic back pain. This trial is focused on understanding how effective AP707 is and how well patients can tolerate it when used alongside their current pain management plan.

What is already known about the treatment

AP707 – AP707 is administered orally in the form of tablets and is currently being studied for its effectiveness and safety in treating chronic back pain. It is in the clinical trial phase, which means it is being tested to see how well it works and how safe it is for patients. The main use of AP707 is to help relieve chronic back pain, especially when used alongside other treatments. At the molecular level, AP707 works by targeting specific pathways in the body that are involved in pain signaling, helping to reduce the sensation of pain. It is classified as an analgesic, which is a type of medication used to relieve pain.

Investigated diseases

Chronic Back Pain – Chronic back pain is a persistent pain that occurs in the back, lasting for more than three months. It can be caused by various factors, including muscle or ligament strain, bulging or ruptured disks, arthritis, or skeletal irregularities. The pain may be felt as a dull ache, sharp pain, or burning sensation, and it can vary in intensity. Over time, chronic back pain can lead to decreased mobility and flexibility, making it difficult to perform daily activities. The condition may also contribute to psychological distress, such as anxiety or depression, due to its persistent nature. As the pain continues, it can affect sleep quality and overall quality of life.
Trial detailsLast updated 7 Oct 2026
Age18+ yearsPhasePhase IIITrial ID2022-502151-54-00Protocol codeDISCOVER_(MBP)Estimated enrolment558 patientsSponsorApurano Pharmaceuticals GmbH

sourced from the EU Clinical Trials Register and site verification

Want to learn more about this trial or check if you can participate?

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.